Literature DB >> 25395995

Pharmacology and Toxicology of Nav1.5-Class 1 anti-arrhythmic drugs.

Dan M Roden1.   

Abstract

Although cardiac sodium channel blocking drugs can exert antiarrhythmic actions, they can also provoke life-threatening arrhythmias through a variety of mechanisms. This review addresses the way in which drugs interact with the channel, and how these effects translate to clinical beneficial or detrimental effects. A further understanding of the details of channel function and of drug-channel interactions may lead to the development of safer and more effective antiarrhythmic therapies.

Entities:  

Keywords:  drugs; proarrhythmia; sodium channel

Year:  2014        PMID： 25395995      PMCID： PMC4226533          DOI： 10.1016/j.ccep.2014.07.003

Source DB:  PubMed          Journal:  Card Electrophysiol Clin        ISSN： 1877-9182


  86 in total

1.  Common sodium channel promoter haplotype in asian subjects underlies variability in cardiac conduction.

Authors:  Connie R Bezzina; Wataru Shimizu; Ping Yang; Tamara T Koopmann; Michael W T Tanck; Yoshihiro Miyamoto; Shiro Kamakura; Dan M Roden; Arthur A M Wilde
Journal:  Circulation       Date:  2006-01-16       Impact factor: 29.690

2.  Flecainide therapy reduces exercise-induced ventricular arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia.

Authors:  Christian van der Werf; Prince J Kannankeril; Frederic Sacher; Andrew D Krahn; Sami Viskin; Antoine Leenhardt; Wataru Shimizu; Naokata Sumitomo; Frank A Fish; Zahurul A Bhuiyan; Albert R Willems; Maurits J van der Veen; Hiroshi Watanabe; Julien Laborderie; Michel Haïssaguerre; Björn C Knollmann; Arthur A M Wilde
Journal:  J Am Coll Cardiol       Date:  2011-05-31       Impact factor: 24.094

3.  Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction.

Authors: 
Journal:  N Engl J Med       Date:  1989-08-10       Impact factor: 91.245

4.  Predicting drug-induced slowing of conduction and pro-arrhythmia: identifying the 'bad' sodium current blockers.

Authors:  Hua Rong Lu; Jutta Rohrbacher; Eddy Vlaminckx; Karel Van Ammel; Gan-Xin Yan; David J Gallacher
Journal:  Br J Pharmacol       Date:  2010-03-22       Impact factor: 8.739

5.  A novel SCN5A arrhythmia mutation, M1766L, with expression defect rescued by mexiletine.

Authors:  Carmen R Valdivia; Michael J Ackerman; David J Tester; Tomoyuki Wada; Jorge McCormack; Bin Ye; Jonathan C Makielski
Journal:  Cardiovasc Res       Date:  2002-08-01       Impact factor: 10.787

Review 6.  Efficacy of quinidine in high-risk patients with Brugada syndrome.

Authors:  Bernard Belhassen; Aharon Glick; Sami Viskin
Journal:  Circulation       Date:  2004-09-20       Impact factor: 29.690

7.  Sudden cardiac arrest associated with use of a non-cardiac drug that reduces cardiac excitability: evidence from bench, bedside, and community.

Authors:  Abdennasser Bardai; Ahmad S Amin; Marieke T Blom; Connie R Bezzina; Jocelyn Berdowski; Pim N J Langendijk; Leander Beekman; Christine A Klemens; Patrick C Souverein; Rudolph W Koster; Anthonius de Boer; Hanno L Tan
Journal:  Eur Heart J       Date:  2013-02-20       Impact factor: 29.983

8.  Molecular mechanisms of the reversal of imipramine-induced sodium channel blockade by alkalinization in human cardiac myocytes.

Authors:  E Bou-Abboud; S Nattel
Journal:  Cardiovasc Res       Date:  1998-05       Impact factor: 10.787

9.  A trafficking defective, Brugada syndrome-causing SCN5A mutation rescued by drugs.

Authors:  Carmen R Valdivia; David J Tester; Benjamin A Rok; Co-Burn J Porter; Thomas M Munger; Arshad Jahangir; Jonathan C Makielski; Michael J Ackerman
Journal:  Cardiovasc Res       Date:  2004-04-01       Impact factor: 10.787

10.  Common variants at SCN5A-SCN10A and HEY2 are associated with Brugada syndrome, a rare disease with high risk of sudden cardiac death.

Authors:  Connie R Bezzina; Julien Barc; Yuka Mizusawa; Carol Ann Remme; Jean-Baptiste Gourraud; Floriane Simonet; Arie O Verkerk; Peter J Schwartz; Lia Crotti; Federica Dagradi; Pascale Guicheney; Véronique Fressart; Antoine Leenhardt; Charles Antzelevitch; Susan Bartkowiak; Martin Borggrefe; Rainer Schimpf; Eric Schulze-Bahr; Sven Zumhagen; Elijah R Behr; Rachel Bastiaenen; Jacob Tfelt-Hansen; Morten Salling Olesen; Stefan Kääb; Britt M Beckmann; Peter Weeke; Hiroshi Watanabe; Naoto Endo; Tohru Minamino; Minoru Horie; Seiko Ohno; Kanae Hasegawa; Naomasa Makita; Akihiko Nogami; Wataru Shimizu; Takeshi Aiba; Philippe Froguel; Beverley Balkau; Olivier Lantieri; Margherita Torchio; Cornelia Wiese; David Weber; Rianne Wolswinkel; Ruben Coronel; Bas J Boukens; Stéphane Bézieau; Eric Charpentier; Stéphanie Chatel; Aurore Despres; Françoise Gros; Florence Kyndt; Simon Lecointe; Pierre Lindenbaum; Vincent Portero; Jade Violleau; Manfred Gessler; Hanno L Tan; Dan M Roden; Vincent M Christoffels; Hervé Le Marec; Arthur A Wilde; Vincent Probst; Jean-Jacques Schott; Christian Dina; Richard Redon
Journal:  Nat Genet       Date:  2013-07-21       Impact factor: 38.330
View more
  6 in total

1.  Computational Analysis of the Mode of Action of Disopyramide and Quinidine on hERG-Linked Short QT Syndrome in Human Ventricles.

Authors:  Dominic G Whittaker; Haibo Ni; Alan P Benson; Jules C Hancox; Henggui Zhang
Journal:  Front Physiol       Date:  2017-10-04       Impact factor: 4.566

2.  The Citrus Flavonoid Hesperetin Has an Inadequate Anti-Arrhythmic Profile in the ΔKPQ NaV1.5 Mutant of the Long QT Type 3 Syndrome.

Authors:  Julio Alvarez-Collazo; Alejandro López-Requena; Julio L Alvarez; Karel Talavera
Journal:  Biomolecules       Date:  2020-06-24

3.  Amiodarone-induced Hyponatremia: A Case Report and a Review of the Literature.

Authors:  Waseem Barham; Samer A Zeayter; Abdulrahman Safadi; Ranjan K Thakur
Journal:  J Innov Card Rhythm Manag       Date:  2018-03-15

4.  Veratridine Can Bind to a Site at the Mouth of the Channel Pore at Human Cardiac Sodium Channel NaV1.5.

Authors:  Alican Gulsevin; Andrew M Glazer; Tiffany Shields; Brett M Kroncke; Dan M Roden; Jens Meiler
Journal:  Int J Mol Sci       Date:  2022-02-17       Impact factor: 5.923

5.  Cardiac sodium channel inhibition by lamotrigine: In vitro characterization and clinical implications.

Authors:  Lindsey Ingleby-Talecki; Sven C van Dijkman; Sean P Oosterholt; Oscar Della Pasqua; Christina Winter; Marianne Cunnington; Linda Rebar; Sergio Forero-Schwanhaeuser; Vickas Patel; James A Cooper; Anthony Bahinski; Khuram W Chaudhary
Journal:  Clin Transl Sci       Date:  2022-05-31       Impact factor: 4.438

6.  In silico Assessment of Pharmacotherapy for Human Atrial Patho-Electrophysiology Associated With hERG-Linked Short QT Syndrome.

Authors:  Dominic G Whittaker; Jules C Hancox; Henggui Zhang
Journal:  Front Physiol       Date:  2019-01-11       Impact factor: 4.566
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.